Comanche Biopharma Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series B2

  • Latest Deal Amount
  • $10M

  • Investors
  • 8

Comanche Biopharma General Information

Description

Operator of a biopharmaceutical company intended to develop an investigational siRNA medicine for preterm preeclampsia. The company provides access to evidence-based and affordable therapies for treating life-threatening complications of pregnancy, enabling women to avail themselves of cost-effective and sustainable preeclampsia treatment at its root cause.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 50 Beharrell Street
  • Unit B
  • Concord, MA 01742
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 50 Beharrell Street
  • Unit B
  • Concord, MA 01742
  • United States
+1 (617)

Comanche Biopharma Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Comanche Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B2) 15-Oct-2025 $10M Completed Generating Revenue
2. Early Stage VC (Series B) 17-Jan-2024 Completed Generating Revenue
1. Early Stage VC (Series A) 28-Jun-2021 $36.1M $36.1M Completed Startup
To view Comanche Biopharma’s complete valuation and funding history, request access »

Comanche Biopharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A 33,341,024 $0.010000 8% $1.08 $1.08 1x $1.08 25.79%
To view Comanche Biopharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Comanche Biopharma Patents

Comanche Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024296743-A1 Formulations of nucleic acid compounds and uses thereof Pending 13-Jul-2023
EP-4743061-A1 Formulations of nucleic acid compounds and uses thereof Pending 13-Jul-2023
US-20260248839-A1 Formulations of nucleic acid compounds and uses thereof Pending 13-Jul-2023
WO-2025015189-A1 Formulations of nucleic acid compounds and uses thereof Inactive 13-Jul-2023 A61K9/0019

Comanche Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Comanche Biopharma Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atlas Venture Venture Capital Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
Longview Healthcare Ventures Venture Capital Minority
New Enterprise Associates Venture Capital Minority
Broadview Ventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Comanche Biopharma FAQs

  • When was Comanche Biopharma founded?

    Comanche Biopharma was founded in 2020.

  • Where is Comanche Biopharma headquartered?

    Comanche Biopharma is headquartered in Concord, MA.

  • What is the size of Comanche Biopharma?

    Comanche Biopharma has 29 total employees.

  • What industry is Comanche Biopharma in?

    Comanche Biopharma’s primary industry is Drug Discovery.

  • Is Comanche Biopharma a private or public company?

    Comanche Biopharma is a Private company.

  • What is the current valuation of Comanche Biopharma?

    The current valuation of Comanche Biopharma is .

  • What is Comanche Biopharma’s current revenue?

    The current revenue for Comanche Biopharma is .

  • How much funding has Comanche Biopharma raised over time?

    Comanche Biopharma has raised $136M.

  • Who are Comanche Biopharma’s investors?

    Atlas Venture, LAV (Lilly Asia Fund), Longview Healthcare Ventures, New Enterprise Associates, and Broadview Ventures are 5 of 8 investors who have invested in Comanche Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process